We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations

This study is currently recruiting participants.
Verified November 2011 by Fowzan Alkuraya, King Khaled Eye Specialist Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT01482195
First Posted: November 30, 2011
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
King Khaled Eye Specialist Hospital
King Faisal Specialist Hospital & Research Center
Information provided by (Responsible Party):
Fowzan Alkuraya, King Khaled Eye Specialist Hospital
  Purpose
A recombinant adeno-associated virus serotype 2 (rAAV2) vector has been altered to carry the human MERTK (hMERTK) gene. This vector has been shown to restore vision in animal models that resemble human MERTK-associated Retinitis Pigmentosa (RP), an incurable retinal degeneration that causes severe vision loss. The proposed study is an open label, Phase I clinical trial of subretinal rAAV2-VMD2-hMERTK administration to individuals with MERTK-associated retinal disease. This trial will lead to a greater understanding of the safety and thereby potential value of gene transfer in MERTK-associated retinal disease and will have implications for other forms of retinal degenerative disease amenable to this type of intervention.

Condition Intervention Phase
Retinal Disease Genetic: Recombinant Adeno-Associated Virus Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations

Resource links provided by NLM:


Further study details as provided by Fowzan Alkuraya, King Khaled Eye Specialist Hospital:

Primary Outcome Measures:
  • Ocular and Systemic safety of uniocular subretinal administration of rAAV2-VMD2-hMERTK in individuals with MERTK-associated retinal disease [ Time Frame: 12 yrs ]

    1.Ocular safety:

    • Keratitis.
    • Glaucoma.
    • Cataract.
    • Uveitis.
    • Vitreous hemorrhage.
    • Retinal detachment.

      2.Systemic Safety:

    • Organs systemic toxicity.
    • Viral Signs:

      1. Antibody titers to AAV capsid components and Antigen-specific Reactivity (ASR) Measurement.
      2. Peripheral Blood PCR.


Secondary Outcome Measures:
  • Visual Outcome [ Time Frame: 12 yrs ]

    Visual function:

    1. ETDRS visual acuity measurement.
    2. Full-field Stimulation Threshold (FST).


Estimated Enrollment: 6
Study Start Date: August 2011
Estimated Study Completion Date: August 2023
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Recombinant Adeno-Associated Virus Genetic: Recombinant Adeno-Associated Virus
Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • MERTK-associated retinal disease;
  • VA: 20/100 or less in worse eye
  • Ability to perform tests of visual and retinal function;
  • Good general health based on a complete physical examination and hematology and chemistry studies performed at a pre-treatment evaluation;
  • Ability to comply with research procedures;

Exclusion Criteria:

  • Pre-existing eye conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints or surgical complications (for example, glaucoma, corneal or lenticular opacities);
  • Complicating systemic diseases (such as medical conditions causing immunosuppression) that would preclude the gene transfer, ocular surgery or known sensitivity or allergy to medications planned for use in the peri-operative period;
  • Use of anti-platelet agents that may alter coagulation within 7 days prior to study agent administration;
  • Use of immunosuppressive medications;
  • Pregnancy or breastfeeding;
  • Individuals (males and females) of childbearing potential who are unwilling to use effective contraception for 1 year following agent administration and barrier contraception for 3 months following agent administration;
  • Any other condition that would prevent a subject from completing follow-up examinations during the course of the study and that, in the opinion of the investigator, makes the subject unsuitable for the study.
  • Current, or recent (within the past 30 days, or 10 half lives of the drug) participation, in any other research protocol involving investigational agents or therapies.
  • Recent (within past 6 months) receipt of an investigational biologic therapeutic agent.Subjects will not be excluded based on their gender, race or ethnicity.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01482195


Contacts
Contact: Fowzan S Alkuraya, MD +966 1 442 7875 falkuraya@kfshrc.edu.sa

Locations
Saudi Arabia
King Khaled Eye Specialist Hospital Recruiting
Riyadh, Saudi Arabia, 11462
Contact: Deepak Edward, MD    96614821234 ext 1362    dedward@kkesh.med.sa   
Principal Investigator: Emad Abboud, MD         
Sponsors and Collaborators
Fowzan Alkuraya
King Khaled Eye Specialist Hospital
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Fowzan S Alkuraya, MD King Faisal Specialist Hospital & Research Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Fowzan Alkuraya, Head, Developmental Genetics Unit, King Khaled Eye Specialist Hospital
ClinicalTrials.gov Identifier: NCT01482195     History of Changes
Other Study ID Numbers: 0916-P
First Submitted: September 28, 2011
First Posted: November 30, 2011
Last Update Posted: October 12, 2017
Last Verified: November 2011

Keywords provided by Fowzan Alkuraya, King Khaled Eye Specialist Hospital:
Retinal Disease

Additional relevant MeSH terms:
Retinal Diseases
Eye Diseases